Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells

被引：35

作者：

Fernandez-Luna, JL ^{[1
]}

机构：

[1] Hosp Univ Marques de Valdecilla, Immunol Unit, Mol Biol Lab, Santander 39008, Spain

来源：

APOPTOSIS | 2000年 / 5卷 / 04期

关键词：

apoptosis; Bcl-x(L); Bcr-Abl; signaling; transcription factor;

D O I：

10.1023/A:1009623222534

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Chronic myelogenous leukemia (CML) cells are highly resistant to apoptosis induced by chemotherapeutic drugs. The observation that production of Bcr-Abl is the initiating event in CML has focussed attention on the survival signals triggered by this oncogene. A number of signal transducers and transcription factors have been associated with the antiapoptotic phenotype of CML cells, some of which lead to the expression and/or activation of members of the Bcl-2 family of apoptosis modulators, such as Bcl-x(L) and Bad. In this article, recent advances in understanding the antiapoptotic pathways triggered by Bcr-Abl in CML cells, are discussed.

引用

页码：315 / 318

页数：4

共 37 条

[21] The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: Roles for phosphatidylinositol 3-kinase and Raf [J].

Neshat, MS ;

Raitano, AB ;

Wang, HG ;

Reed, JC ;

Sawyers, CL .

MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (04) :1179-1186

[22]

PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7

[23] A requirement for NF-κB activation in Bcr-Abl-mediated transformation [J].

Reuther, JY ;

Reuther, GW ;

Cortez, D ;

Pendergast, AM ;

Baldwin, AS .

GENES & DEVELOPMENT, 1998, 12 (07) :968-981

[24]

Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0

[25]

Shuai K, 1996, ONCOGENE, V13, P247

[26] STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells [J].

Sillaber, C ;

Gesbert, F ;

Frank, DA ;

Sattler, M ;

Griffin, JD .

BLOOD, 2000, 95 (06) :2118-2125

[27] Erythropoietin can induce the expression of Bcl-xL through Stat5 in erythropoietin-dependent progenitor cell lines [J].

Silva, M ;

Benito, A ;

Sanz, C ;

Prosper, F ;

Ekhterae, D ;

Nuñez, G ;

Fernandez-Luna, JL .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (32) :22165-22169

[28]

SIRARD C, 1994, BLOOD, V83, P1575

[29] The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: Role in adhesion, invasion, and homing [J].

Skorski, T ;

Nieborowska-Skorska, M ;

Wlodarski, P ;

Wasik, M ;

Trotta, R ;

Kanakaraj, P ;

Salomoni, P ;

Antonyak, M ;

Martinez, R ;

Majewski, M ;

Wong, A ;

Perussia, B ;

Calabretta, B .

BLOOD, 1998, 91 (02) :406-418

[30] Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway [J].

Skorski, T ;

Bellacosa, A ;

NieborowskaSkorska, M ;

Majewski, M ;

Martinez, R ;

Choi, JK ;

Trotta, R ;

Wlodarski, P ;

Perrotti, D ;

Chan, TO ;

Wasik, MA ;

Tsichlis, PN ;

Calabretta, B .

EMBO JOURNAL, 1997, 16 (20) :6151-6161

← 1 2 3 4 →